Vanguard Global Advisers »

Kalaris Therapeutics shares owned by Vanguard Global Advisers

Quarter-by-quarter ownership of Kalaris Therapeutics (KLRS) shares owned by Vanguard Global Advisers from 13F filings

Historical chart of Vanguard Global Advisers investment in Kalaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kalaris Therapeutics held by Vanguard Global Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kalaris Therapeutics by Vanguard Global Advisers

Quarter filed Position value Share count Share price at filing
2026-03-31 $4.2k 725 5.77

More positions owned by Vanguard Global Advisers

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Vanguard Index Fds Total Stk Mkt (VTI)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Alphabet Cap Stk Cl C (GOOG)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
JPMorgan Chase & Co. (JPM)

View all positions for Vanguard Global Advisers

Top funds holding Kalaris Therapeutics

Samsara BioCapital
Rtw Investments
Paradigm Biocapital Advisors
Alyeska Investment Group
Siren
Ikarian Capital
Propel Bio Management
Vanguard Group
Vanguard Capital Management
Kalehua Capital Management
Goldman Sachs Group
Woodline Partners
ADAR1 Capital Management
Whi Trust
Boothbay Fund Management

View all funds holding Kalaris Therapeutics